

APPLIED GENETIC TECHNOLOGIES CORP  
Form 8-K  
August 18, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 17, 2016

APPLIED GENETIC TECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

Delaware  
(State or Other Jurisdiction

001-36370  
(Commission File Number)

59-3553710  
(IRS Employer

of Incorporation)

Identification No.)

14193 NW 119<sup>th</sup> Terrace

Suite 10

Alachua, Florida  
(Address of Principal Executive Offices)

32615  
(Zip Code)

Registrant's Telephone Number, Including Area Code: (386) 462-2204

Not Applicable

Edgar Filing: APPLIED GENETIC TECHNOLOGIES CORP - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition

On August 17, 2016, our board of directors appointed Anne M. VanLent to serve on our board of directors as a class I director. Ms. VanLent's term will expire at our annual meeting of stockholders for fiscal year 2017. Ms. VanLent was also appointed to serve as the chairperson of our audit committee.

A copy of our press release dated August 18, 2016 announcing the appointment of Ms. VanLent to our board of directors is attached as Exhibit 99.1 to this Current Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
-------------	-------------

99.1	Press release dated August 18, 2016, entitled "AGTC Appoints Anne M. VanLent to its Board of Directors."
------	--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

APPLIED GENETIC  
TECHNOLOGIES  
CORPORATION

Date: August  
18, 2016      By: /s/ Lawrence E. Bullock  
Lawrence E. Bullock  
Chief Financial Officer

Exhibit Index

Exhibit No. Description

99.1 Press release dated August 18, 2016, entitled "AGTC Appoints Anne M. VanLent to its Board of Directors."